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Abstract: Patients with chronic kidney disease have a high burden of cardiovascular morbidity 
and mortality. The vast majority of patients with chronic kidney disease do not progress to end 
stage renal failure, but do have a significantly higher incidence of all cardiovascular co-morbidities. 
Traditional cardiovascular risk factors only partially account for this increased incidence of 
cardiovascular disease. In patients with kidney disease the basic biology underlying cardiovascular 
disease may be similar to that in patients without kidney disease, but it would seem many more 
risk factors are involved as a consequence of renal dysfunction. Although emphasis is placed on 
delaying the progression of chronic kidney disease, it must be appreciated that for many patients 
it is vital to address their cardiovascular risk factors at an early stage to prevent premature car-
diovascular death. This review examines available epidemiological evidence, discusses common 
cardiovascular risk factors in patients with chronic kidney disease, and suggests possible treatment 
strategies. Potential areas for important research are also described.
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Introduction
Cardiovascular disease in patients with chronic kidney disease (CKD) is common and 
has major implications in terms of both human suffering and health economics. CKD 
is defined by the presence of kidney damage and level of kidney function – irrespective 
of the type of kidney disease. Among individuals with chronic kidney disease, the 
stages are defined by the level of kidney function, and CKD stage 3 comprises 
those with a stable, or gradually declining, estimated glomerular filtration rate 
(eGFR) 30 to 60 mL/min/1.73 m2.
Recognition of kidney disease has increased greatly in recent years, partly due to the 
widespread introduction of eGFR reporting, and partly as a result of the aging popula-
tion which has an increasing prevalence of hypertension and diabetes – conditions 
in which minor kidney disease is very common, and clinically significant kidney 
disease is unfortunately often recognized too late to halt the relentless decline in 
kidney function. As a result of government initiatives UK primary care physicians 
are now keeping registers of patients with CKD in the same way that they have pre-
viously compiled them for diabetes and ischemic heart disease (IHD). Consequently 
the number of new patient referrals to nephrology clinics has soared over the last few 
years, and yet the key elements of hypertension and cardiovascular disease are often 
inadequately managed.
Once patients reach end stage kidney disease (CKD stage 5) and enter dialysis 
programs, they have an alarmingly high rate of cardiovascular death with those in Vascular Health and Risk Management 2009:5 714
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the youngest age range of 25 years having equivalent 
cardiovascular mortality rates to 75- to 85-year-olds in the 
general population.1 Hence there is now increasing interest 
in the cardiovascular status of patients with earlier stages of 
CKD where efforts can be made to prevent cardiovascular 
disease occurring. Most patients with CKD do not suffer from 
symptoms of uremia, nor indeed die from kidney disease. 
The majority of patients with CKD die from cardiovascular 
disease, before their kidney dysfunction requires replace-
ment therapy. In this review, we examine the evidence for 
increased cardiovascular disease in patients with CKD and 
suggest potential areas for research and treatment which may 
lessen the disease burden.
Epidemiological evidence  
for increased cardiovascular  
disease in patients with CKD
When compared to age-matched controls with normal kidney 
function, patients with CKD have markedly higher cardio-
vascular mortality which is multifactorial in origin2. Perhaps 
directly because of this high mortality, patients with severe 
CKD have largely been excluded from interventional trials 
aimed at reducing cardiovascular risk, including trials of 
angiotensin converting enzyme inhibitors (ACEi) and statins. 
Kidney disease is also a catabolic state and the syndrome of 
malnutrition, inflammation and atherosclerosis is prevalent 
in patients with kidney disease, particularly once they reach 
CKD stage 5 (eGFR  15mL/min), with constant activation 
of many acute phase proteins and cytokines.3 These observa-
tions mean that it is difficult to tease out the influence of one 
particular factor in the overall increased risk of cardiovascular 
morbidity and mortality in patients with CKD.
The NEOERICA study of computerized records in UK 
primary care has produced useful data demonstrating the 
influence of CKD on the prevalence of cardiovascular co-
morbidities.4 This key study established that the prevalence 
of IHD at approximately 25% for the patient population with 
CKD 3 to 5 (eGFR  60 mL/min) was more than double that 
of patients without CKD. This marked increase in prevalence 
is also seen for congestive cardiac failure, peripheral vascular 
disease and cerebrovascular disease.
Once patients progress to eGFR  45 mL/min then 
cardiovascular disease burden is increased compared to indi-
viduals with more preserved renal function.5 The presence of 
any cardiovascular disease, be it congestive cardiac failure, 
IHD or left ventricular hypertrophy (LVH), predicts a faster 
decline in kidney function when adjusted for baseline GFR.6 
This suggests that cardiovascular co-morbidity is itself a risk 
factor for kidney functional decline most likely through an 
enhanced inflammatory process. The scale of the problem 
is exemplified by the fact that at the time of referral to a 
nephrologist approximately one third of patients with CKD 
already have evidence of IHD.
The NEOERICA study also demonstrated that greater 
than 50% of primary care patients of the age 85 years or 
older have CKD, although whether this is simply evidence 
of a normal aging process remains a controversial point. 
This might suggest that much CKD is clinically irrelevant 
as many such patients are not symptomatic and the use of 
cardiovascular risk reduction strategies in this age group has 
questionable benefits with regard to reduction in mortality 
and morbidity. Therefore the challenge currently facing 
nephrologists is to establish the clinical relevance of reduced 
kidney function in an individual patient. It may be that the 
key point is management of cardiovascular risk rather than 
management of reduced GFR.
For patients with CKD, long term population follow-up 
studies have shown that even for those with severe CKD 
(eGFR 15 to 30 mL/min), there is a much higher likelihood 
of death than of commencing dialysis (45.7% vs 19.9% 
incidence respectively over 5 years).7 Yet in patients with 
severe CKD, more emphasis is often placed on preparation 
for kidney replacement therapy, including discussion of the 
differing dialysis modalities and kidney transplantation work 
up, than cardiovascular risk reduction. In patients whose 
kidney dysfunction is managed by primary care physicians, 
the standardized mortality rate for those with CKD under 
60 years of age is much higher than for older patients. This 
leads to the conclusion that patients under the age of 60 with 
early CKD may have the most to gain from cardiovascular 
risk factor manipulation.
Risk factors for cardiovascular 
disease in patients with CKD
Patients with CKD have higher rates of cardiovascular 
morbidity and mortality than would be predicted by 
Framingham models of cardiovascular risk.8 There are 
many reasons for this including importantly, the confound-
ing additional cardiovascular risk arising from malnutrition 
which occurs because kidney dysfunction leads to a catabolic 
state. This then promotes inflammation, a key promoter in 
the development of cardiovascular disease.9 There are also 
several paradoxical associations of traditional cardiovascular 
risk factors seen in patients with CKD. Once patients are on 
dialysis, a high body mass index leads to lower cardiovascular 
risk than a low body mass index in contradiction to general Vascular Health and Risk Management 2009:5 715
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population studies.10 Another interesting association is the 
‘J-shaped curve’ effect of both cholesterol and systolic blood 
pressure with cardiovascular morbidity and mortality which 
is observed in patients with CKD.11,12
The effect of statins and other cholesterol lowering agents 
in CKD is as yet uncertain. Studies of transplant patients 
given Fluvastatin failed to show an overall reduction of car-
diovascular morbidity or mortality13,14 and in type 2 diabetes 
patients on hemodialysis, atorvastatin had no significant 
effect on cardiovascular death, non fatal myocardial infarc-
tion or stroke.15 Perhaps the cardiovascular risk of patients 
receiving kidney replacement therapy in the form of dialysis 
or transplantation is too high to show a clear benefit from 
cholesterol reduction, suggesting that it is in patients with 
earlier stages of CKD that the health benefits of cardiovas-
cular risk reduction might be maximized.
The traditional risk factors for cardiovascular disease 
such as hypertension, dyslipidemia, diabetes and obesity 
are highly prevalent in CKD populations. However there 
are many other cardiovascular risk factors that are either 
‘uremia specific’, or at least much more common in patients 
with CKD than in the general population. These factors 
include anemia, hyperparathyroidism, carnitine deficiency, 
hyperhomocysteinemia, low vitamin C, high lipoprotein(a) 
levels and small apolipoprotein(a) size. To be of relevance 
clinically, treatment of individual risk factors must be able to 
be generalized to a diverse population. In addition, the risk 
factor must be modifiable with a demonstrable improvement 
in cardiovascular outcome. An example from nephrology 
where this has not been the case is hyperhomocysteinemia. 
Hyperhomocysteinemia is associated with poor cardiovascu-
lar prognosis in dialysis patients and the levels can be brought 
under control by supplementation with pyridoxine, vitamin 
B12 and folic acid. However such modification has not been 
shown to be reliable in reducing cardiovascular risk in kidney 
patients so that measurement of serum homocysteine, and 
treatment of elevated levels, is not widespread practice.
Anemia exerts a large influence over the pathogenesis 
of LVH, and correction with erythropoietin has been shown 
to reduce LVH.16 However this is also not straightforward. 
In studies where full correction of anemia has been compared 
with partial correction, the fully corrected group had a higher 
incidence of non fatal myocardial infarction than patients in 
whom anemia was only partially corrected.17 Malnutrition 
is another major factor in patients with CKD, and can be 
the cause or effect of the chronic low grade inflammation 
frequently present in CKD. Both these cardiovascular risk 
factors are amenable to correction with careful assessment 
and treatment involving a multidisciplinary team comprising 
anemia specialist nurses and specialist renal dieticians.
Diabetes and CKD
Diabetic patients with CKD often present the most challenges 
for the nephrologist. Such patients have a higher incidence 
of cardiovascular co-morbidities such as IHD and peripheral 
vascular disease than any other patient group with CKD. 
The relationship between type 2 diabetes and hypertension 
is particularly strong with 79% of patients having either 
hypertension or abnormal circadian blood pressure cycles 
at the time of diagnosis.18 It is postulated that proteinuria 
reflects endothelial dysfunction so is a marker for increased 
risk of cardiovascular disease. Mortality in diabetes patients 
becomes strikingly high with the onset of proteinuria. 
General measures to reduce vascular risk in diabetes 
patients apply with the addition of good diabetes control. 
Trials of intervention for diabetes patients with respect to 
kidney impairment have focused on reducing conversion 
of normalbuminuria to microalbuminura,19,20 delaying the 
onset of diabetes nephropathy in type 2 diabetes patients 
with microalbuminura21,22 and delaying progressive kidney 
impairment once diabetes nephropathy has occurred,23,24 These 
interventions all involved blockade of the renin-angiotensin 
system (RAS). Interestingly, by the time patients have 
established diabetes nephropathy, intervention with RAS 
blocking agents has not been shown to alter cardiovascular risks 
overall, inferring that it is vital to commence treatment early in 
the pathway of kidney damage in patients with diabetes in order 
to affect their cardiovascular outcome. A post-hoc analysis 
of the Irbesartan in Diabetic Nephropathy Trial did show an 
overall mortality benefit for those patients with systolic blood 
pressure 120 mm Hg compared to those patients with higher 
systolic blood pressure.25
The Steno-2 trial demonstrated a 50% reduction in micro-
vascular and microvascular complications in type 2 diabetes 
patients with microalbuminuira randomized to an intensive 
treatment arm with close attention paid to blood pressure, 
glycemic control, lipids and lifestyle measure; thus even in 
diabetes patients cardiovascular risk can be reduced with 
appropriate measures.26
Hypertension and CKD
As a potentially modifiable risk factor, the impact of 
hypertension on cardiovascular disease in patients with 
CKD is of great interest. As kidney impairment progresses 
there is increasing activation of the RAS in response to 
glomerular sclerosis and interstitial disease as well as Vascular Health and Risk Management 2009:5 716
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fluid overload and increased arterial stiffness, all of which 
contribute to hypertension. Essential hypertension itself 
causes microvascular damage in the renal vascular bed 
causing kidney damage and hence, through RAS activation, 
exacerbating essential hypertension. Hypertension is known 
to alter renal physiological function with increased filtration 
fraction of sodium and increased renovascular resistance seen 
in hypertensive patients.27
Poor hypertension control clearly leads to increasing risk 
of cardiovascular morbidity and mortality and increasing risk 
of declining kidney function. A ‘vicious circle’ is created 
with worsening kidney function itself then contributing 
to hypertension. Hypertension is widespread among an 
otherwise healthy general population, especially in the 
elderly where approximately two thirds of people will 
be hypertensive. The majority of patients with CKD are 
hypertensive, with the prevalence increasing with increasing 
severity of CKD such that in the most severe stages of CKD 
(eGFR  30 mL/min) over 90% of patients are hypertensive.3 
As CKD progresses there is also increasing loss of the physi-
ological nocturnal ‘dip’ in blood pressure, which is in itself 
a marker for the presence of LVH.28
Studies have clearly shown a significant reduction in the 
rate of progression of CKD when hypertension is treated. 
Particularly this has been demonstrated in major studies 
investigating blockade of the RAS with ACEi in both 
proteinuric and nonproteinuric CKD29 and with angiotensin II 
receptor blockers.15,16 Many studies have demonstrated a 
reduction in the rate of progression of CKD with drugs block-
ing the RAS, compared to the same blood pressure reduction 
achieved with other antihypertensive regimens. This alludes to 
the importance of blocking angiotensin II which is a powerful 
an endothelial growth factor in the renal vascular bed, 
as well as the body’s most powerful vasoconstrictor. There 
is not currently a full understanding of the pathophysiology 
of the effects of hypertension on the kidney in patients with 
CKD; however the major effect is likely to be a progressive 
increase in intra-renal vascular resistance which may precede 
any changes in kidney structure.
The Hypertension Detection and Follow Up Program 
followed over 10,000 general population patients over 
5 years in a randomized controlled trial comparing usual 
antihypertensive care with a stepped program of drug 
interventions to achieve reduction in diastolic blood pressure 
of 10 mm Hg (or 90 mm Hg in those patients whose 
baseline diastolic blood pressure was 100 mm Hg). As well 
as a 17% reduction in mortality, this trial established that 
the incidence of decline in kidney function was less in the 
stepped blood pressure treatment group than in other patients. 
The incidence of decline in kidney function was greatest in 
men and older adults as well as those with higher baseline 
diastolic blood pressure. The incidence of significant kidney 
impairment was low in this community based study, however 
an elevated serum creatinine was a potent independent risk 
factor for mortality. The lower rate of kidney impairment in 
the intensive blood pressure treatment group demonstrates 
the value of aggressive hypertension management in patients 
with CKD even in the early stages of kidney dysfunction.30 
A smaller US study of patients with treated hypertension and 
initially normal serum creatinine levels also demonstrated 
that 15% of patients, went on to develop kidney dysfunction 
despite adequate blood pressure control.31
Altered kidney function is an adverse prognostic factor 
in populations with essential hypertension as well as in other 
patient populations, such as those with advanced congestive 
cardiac failure or a previous myocardial infarction. Even in 
the absence of a known primary kidney pathology, markers 
for kidney dysfunction (reduced eGFR, microalbuminuria 
and overt proteinuria) should be investigated in these popu-
lations because of the adverse prognostic implications of 
kidney dysfunction. In a study of patients with identified 
primary kidney diseases, elevated mean arterial blood pres-
sure was independently correlated with a decrease in kidney 
function over time.32 Thus both in patients with essential 
hypertension and in those with primary kidney diseases and 
secondary hypertension, controlling blood pressure is an 
important means of reducing the rate of kidney decline as 
well as cardiovascular risk.
There is still debate about the ideal target level of blood 
pressure for patients with CKD. A meta-analysis of random-
ized controlled trials of ACEi showed that whilst increasing 
systolic blood pressure, above 120 mm Hg, proportion-
ately increased the risk of progressive kidney dysfunction; 
increased risk was also seen with systolic blood pressures 
below 110 mm Hg. This finding can probably be explained by 
relative hypoperfusion of the kidney in patients with low sys-
tolic blood pressure secondary to heart failure.7 Such studies 
might lead clinicians to assume that there is a very narrow 
range of blood pressure which can be considered ‘ideal’ for 
patients with CKD. The current British Renal Association 
guidelines suggest a target blood pressure of 130/80 mm Hg 
to be acceptable in patients with stable kidney function and 
a target blood pressure of 125/75 mm Hg in patients with 
proteinuric kidney disease.33
In practice, it is often very difficult to achieve reasonable 
blood pressure control without resorting to polypharmacy, Vascular Health and Risk Management 2009:5 717
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the side effects of which may not be acceptable to patients. 
In elderly patients who have a high incidence of postural 
hypotension, more individualized blood pressure targets 
may need to be set. General population studies such as 
the Hypertension Optimal Treatment study suggest that 
there is a clear advantage of minor reductions in blood 
pressure in terms of cardiovascular outcomes and physicians 
should therefore take heart that even small blood pressure 
reductions may have great benefit for individual patients 
over time.34 Similarly the Ramipril Efficacy in Nephropathy 
study demonstrated that adverse renal outcome (doubling of 
serum creatinine or the need for renal replacement therapy) 
was reduced with a minor reduction in blood pressure in the 
ramipril arm of the study compared to the placebo arm.20 
Overall average blood pressure achieved in this study was 
suboptimal compared to recent targets, again suggesting that 
any blood pressure reduction is important even if targets 
are not achieved.
Vascular calcification
In the general population, atherosclerotic disease is manifest 
by intimal fibro-fatty plaque formation which may then 
become calcified. However, the medial layer of elastic arter-
ies may also be involved in atherosclerosis with thickening 
and calcification occurring. This phenomenon, so called 
medial calcinosis, is associated with increased pulse wave 
velocity, elevated pulse pressure and systolic hypertension. 
Medial calcinosis is more common in diabetes patients, the 
elderly, and patients with CKD. It is known to be associated 
with increased cardiovascular mortality in patients with 
CKD35 and diabetes patients without CKD.36
In elderly patients on dialysis there is evidence of greatly 
increased coronary artery calcification scores, as measured 
by electron beam computerized tomography, compared to 
age matched controls with no kidney impairment but angio-
graphically proven coronary artery disease.37 Further studies 
in dialysis patients, have demonstrated increased mortality 
associated with increased coronary artery calcification,38 
an association of coronary artery calcification with LVH,39 
and an association of increased valvular calcification with 
mortality in patients with CKD.40
As with many aspects of cardiovascular disease in CKD 
patients there is a lack of knowledge regarding the process 
of vascular calcification in the early stages of CKD. Yet there 
is increasing evidence that abnormal bone mineralization 
which occurs early in the course of CKD, and vascular 
calcification are linked. Arterial calcification involves the 
transformation of vascular smooth muscle cells into bone 
forming osteoblast-like cells that express bone matrix 
proteins which are involved in arterial calcification.41
Several non-traditional risk factors for cardiovascular 
disease, which are highly prevalent in patients with CKD, 
can accelerate vascular calcification. These include hyper-
phosphatemia, hyperparathyroidism, hyperhomocysteinemia 
and increased levels of advanced glycosylation end products. 
Excess calcium can also induce smooth muscle cell miner-
alization in vitro.42
Both high and low bone turnover states occur in 
kidney patients. In high bone turn over, both osteoblast 
and osteoclast activity is high preventing adequate miner-
alization of the newly formed bone. In low bone turnover 
(adynamic bone) excessive hypercalcemia is common 
because the skeleton cannot act as an efficient ‘sump’ or 
buffer for calcium or phosphate. The situation is further 
complicated by calcium containing oral phosphate binders 
taken by patients in an effort to prevent gastro-intestinal 
phosphate absorption.
In dialysis patients there are links between decreased bone 
mineral density and increased coronary artery calcification.43 
Peritoneal dialysis patients with biopsy proven adynamic 
bone disease had a 90% incidence of vascular calcification 
seen on plain x-ray compared to 35% of those without ady-
namic bone disease.44
There is no doubt that both high and low bone turnover 
states carry risks for vascular calcification and that whist 
controlling hyperphosphatemia is of paramount importance 
in patients with CKD, a high calcium containing phosphate 
binder load is probably undesirable given our current state 
of knowledge. However, there is a paucity of research in 
this field in both dialysis patients and in the pre dialysis 
phase of CKD. Studies have shown that the progression of 
coronary calcification in patients new to hemodialysis is less 
for patients taking noncalcium-containing phosphate binders 
than for those taking calcium containing binders.45 Although 
a mortality benefit has yet to be proven in the overall hemo-
dialysis population, a reduction in all-cause mortality for 
patients over 65 years of age has been demonstrated after 
2 years sevelamer usage compared to patients on a calcium-
based phosphate binder.46
Now that effective phosphate binders are available which 
do not contain calcium (sevelamer and lanthanum) and do 
not carry the risks associated with aluminium-based bind-
ers, studies can be performed to assess the risks of taking 
calcium containing versus noncalcium-containing binders 
on long-term cardiovascular outcomes in patients with early 
and severe CKD.Vascular Health and Risk Management 2009:5 718
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Genetic pathways are also likely to be important in 
vascular calcification. Fetuin-A is a circulating inhibitor of 
vascular calcification and has been shown to be inversely cor-
related with coronary artery calcification in dialysis patients.47 
Genetic variations in Fetuin-A may explain the variable 
vascular calcification seen in CKD patients. Loss of fibroblast 
growth factor 23 is also implicated in vascular calcification and 
is another example of genetic variation between individuals 
which may influence calcification in CKD.
Left ventricular hypertrophy  
in CKD
In patient populations on renal replacement therapy, LVH is 
an independent risk factor for cardiovascular related death 
which accounts for approximately 45% of mortality. Even 
in the early stages of kidney impairment, the prevalence of 
LVH is higher than in the general population. In a prospec-
tive echocardiographic study by Levin of patients attending a 
renal insufficiency clinic, LVH was present in 27% of patients 
with a creatinine clearance over 50 mL/min. In patients with 
clearances of 25 to 50 mL/min and less than 25 mL/min, the 
prevalence of LVH was 31% and 45% respectively. These 
were significant differences between the functional groups, 
with the major predictors of LVH in this study being systolic 
hypertension and anemia.48
The cardiomyopathy of kidney failure results largely from 
pressure and volume overload, leading to changes which are, 
at least in the early phase, adaptive compensations in order 
to maintain adequate stroke volume.49 Pressure overload, 
resulting from hypertension and related to arterial stiffness 
and vascular calcification leads predominantly to concentric 
LVH. Volume overload could be assumed to cause predomi-
nantly left ventricular dilatation, resulting from salt and water 
overload, but anemia is another factor which might contribute 
to dilatation of the ventricle. The resulting cardiomyopathy 
leads to both left ventricular systolic and diastolic dysfunc-
tion. Systolic dysfunction in uremic patients has been well 
studied and it thought to be the result of premature myocyte 
death for which both IHD and the uremic environment are 
both predisposing factors.
Echocardiographic studies of patients at dialysis inception 
have revealed severe systolic dysfunction (LV ejection fraction 
of 25%) in 15% of patients, with 74% of patients having 
LVH and 32% of patients demonstrating LV dilatation.50 
Such LV abnormalities have been shown to have a direct 
influence on prognosis once patients begin dialysis. Practi-
cally such findings underlie the congestive cardiac failure 
suffered by dialysis patients which is then greatly exacerbated 
by volume overload and hypertension – both highly prevalent 
in this patient population. The advent of imaging techniques 
superior to echocardiography, such as cardiac magnetic 
resonance scanning has led to a new perspective on uremic 
cardiomyopathy. LVH has been demonstrated by late gado-
linium enhancement on magnetic resonance imaging to be 
the predominant form of uremic cardiomyopathy with sub-
endocardial fibrosis secondary to ischemia being an equally 
common finding.51
Most studies have been performed in patients already 
on renal replacement programs, but the evolution of such 
left ventricular morphological changes as CKD progresses 
remains largely unstudied. One might expect that early cor-
rection of anemia and strict hypertension control may slow 
down the development of LVH in patients with CKD. Such 
evidence already exists in dialysis patients with regards to the 
effect of increased hemoglobin levels, attained with the use 
of recombinant erythropoietin, leading to a decrease in LV 
mass and LV end diastolic volume, both surrogate markers 
for LVH.16,52 However no such robust data exist to date in 
patients with earlier stages of CKD.
Potential areas for cardiovascular 
research in patients with CKD
Currently, the nephrology referral guidelines for patients with 
moderate CKD (eGFR 30 to 60 mL/min) in the UK primary 
care setting rely on determining which patients have pheno-
typic features leading physicians to suspect that progressive 
kidney dysfunction is likely to occur. These features include 
hypertension which is poorly controlled despite the utilization 
of several classes of antihypertensive medications, progres-
sive decrease in eGFR (5 mL/min/year), the presence of 
hematuria, significant proteinuria, normochromic anemia, 
electrolyte imbalances and a significant (15%) fall in eGFR 
after the introduction of drugs blocking the RAS. These fea-
tures are associated with the need for further investigation or 
specialist treatments; however they do not accurately predict 
which patients will actually progress to requiring kidney 
replacement. Epidemiologically such patients are certainly 
at high risk of cardiovascular morbidity and mortality and 
this provides an opportunity to study the relationship between 
cardiovascular and kidney disease at an earlier stage than has 
previously been examined.
A key question is whether it is the same inflammatory 
process that drives both progression of kidney dysfunction 
and LVH. As angiotensin II is such a potent growth 
factor promoting LV hypertrophy and fibrosis as well as 
glomerular sclerosis all via the AT1 receptor, one might Vascular Health and Risk Management 2009:5 719
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predict a common etiology.53 However whether advancing 
kidney disease itself promotes conditions under which there 
are enhanced effects of angiotensin II and other cytokines, 
remains the subject of current research. Candidate cytokines 
include interleukins 6 and 10, tumour necrosis factor, tissue 
growth factor beta, vascular endothelial growth factor 
(VEGF), C reactive protein and troponins. The complex 
interplay of these cytokines along with the persistent acute 
phase reaction and low level inflammation which occurs as 
kidney failure progresses in conjunction with malnutrition 
leading to heart failure, atherosclerosis and death is still to 
be fully mapped out.
In addition to the effects of cytokine load, it is clear 
that genotype is also important in determining the outcome 
of kidney dysfunction in patients with CKD. In general 
population studies, the homozygous deletion (D/D) ACE 
gene polymorphism is associated with high LV mass54 and 
is a marker of atherosclerotic complications and nephropathy 
in diabetes patients.55 Interestingly, meta-analyses of asso-
ciations between cardiovascular and kidney disorders have 
not shown the D allele of the ACE gene to be associated 
with hypertension. The effect of ACE gene polymorphism 
on kidney outcome was demonstrated in 1996 with the del-
eterious effect of the D rather than the I allele of the ACE 
gene, with a steeper reciprocal creatinine versus time plot for 
patients homozygous for the deletion allele (D/D) compared 
to the insertion (I/I) allele. For patients with a baseline creati-
nine over 200 µmol/L, the I/I polymorphism was beneficial 
in terms of kidney outcomes. However, such an effect was 
only seen in patients with glomerular disease and not seen 
in patients with tubulo-interstitial disease.56 Once patients 
are on dialysis the D allele is also associated with increased 
cerebrovascular disease and carotid artery stenosis.57 Hence, 
although these effects are not fully understood, the ACE gene 
polymorphism clearly holds prognostic significance in terms 
of cardiovascular disease in patients with CKD.
Intuitively, other genetic polymorphisms must also be 
involved in determining vascular disease in patients with 
kidney impairment. One candidate, VEGF, is known to 
have certain polymorphisms associated with progression of 
kidney impairment in glomerulonephritis.58 VEGF is a plate-
let derived growth factor, which is an important signaling 
protein in angiogenesis and should be the subject of further 
research to delineate its effect on cardiovascular disease in 
renal patient populations.
Yet another area of interest is metabolomics and 
the information that might be gleaned from breakdown 
products of metabolism appearing in a patient’s urine. 
Certain substances such as Interleukin 18 and neutrophil 
gelatinase-associated lipocalcin are urinary markers of acute 
kidney injury in circumstances such as contrast induced 
nephropathy post coronary angiography.59 At low levels 
they may also be markers of kidney ischemia in patients with 
CKD and allow profiling of patients based on risk of kidney 
or cardiovascular disease progression.
Genomics, metabolomics and the cytokine load might 
combine to produce a patient phenotype in which the risk of 
progressive cardiovascular disease in CKD might be high. 
Defining this phenotype is already in progress in the UK 
with the keeping of registers of patients with CKD stage 3 in 
primary care which will no doubt inform large-scale studies 
of progressive disease and in time interventional trials.
Treatment of cardiovascular risk  
in patients with CKD
In most large-scale cardiovascular intervention trials, patients 
with significant kidney impairment have been systematically 
excluded because of the high burden of cardiovascular co 
morbidity and mortality carried by this patient population. 
Hence most cardiovascular disease preventative treatment 
regimens in patients with CKD are currently based on trials 
in a nonrenal population.
Lifestyle measures such as regular exercise and a healthy 
diet are of importance and perhaps the long-term relationship 
between patient and physician in CKD lends itself to regular 
exhortation and encouragement in this direction. In particular 
salt restriction (target sodium intake 100 mmol/day) is 
certainly important in hypertensive patients or those with 
signs or symptoms of fluid overload. Smoking cessation is 
also of primary importance although the support for patients 
in the form of smoking cessation counsellors and clinics is 
often woefully lacking.
Hypertension may be the cause or effect of CKD. How-
ever, it is clear that poor blood pressure control leads to 
increased risk of progressive kidney impairment through 
the mechanisms of hyperfiltration and this is evidenced 
by proteinuria. Poor blood pressure control also increases 
risks of vascular disease in patients with CKD. In view 
of this, treatment should be aggressive, and strict targets 
aimed for (130/80 mm Hg in patients without proteinuria 
and 125/75 mm Hg in patients with diabetes mellitus or 
proteinuria).
There is evidence for benefit of drugs that block the RAS 
that is disproportionately greater than, and in addition to, their 
effect on lowering blood pressure. However the evidence 
for this benefit in CKD with proteinuria, in both diabetes Vascular Health and Risk Management 2009:5 720
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and nondiabetes subjects, cannot be generalized to patients 
without proteinuria. There are good theoretical reasons for 
thinking that dual blockade of angiotensin II with both ACEi 
and angiotensin II receptor blockade might be additionally 
beneficial. Such regimens have been shown to be useful 
in patients with LV dysfunction in general populations60,61 
as well for enhanced proteinuria reduction in patients with 
proteinuric kidney disease of nondiabetic62 or diabetic 
origin.63 Treatment with dual blockade of the RAS must 
be carefully considered in light of the recent ONTARGET 
trial.64 The results of this trail are somewhat worrying with 
respect to patients with CKD as dual blockade of RAS led 
to worse renal outcomes.
If such regimens are employed, patients should be 
warned of the dangers of continuing such medications with 
intercurrent volume depleting illness such as diarrhea and 
vomiting. It is also important that kidney function is checked 
before treatment is commenced and within one to two weeks 
of starting medication to ensure that kidney function has not 
deteriorated significantly. A physiological drop in eGFR of 
up to 15% may be tolerated but in significant renal artery 
stenosis or critical renal perfusion in patients with heart 
failure, the drop in eGFR may be increased and preclude the 
use of such medications.
Often at least three antihypertensive medications with 
differing mechanisms are required to achieve adequate blood 
pressure control. Loop diuretics are particularly effective 
alongside salt and water restriction. The nondihydropyridine 
ring calcium channel blockers also have a place in the 
treatment of hypertension in patients with CKD. If further 
classes of drug are needed, beta blockers, centrally acting 
agents, alpha blockers, and vascular smooth muscle relaxants 
all have a place within multiple drug regimens.
As most of the large scale cholesterol lowering trials 
excluded patients with severe CKD, targets for cholesterol 
are not specific to CKD patients but are assumed to be the 
same as those for secondary prevention of cardiovascular 
disease – total cholesterol 4.0 mmol/L and low-density 
lipoprotein cholesterol 2.0 mmol/L. In patients with end 
stage kidney failure both the 4D study (in diabetes hemo-
dialysis patients) and ALERT study (in transplant patients) 
failed to show an overall benefit of statin therapy in reduc-
ing cardiovascular risk in patients with CKD. There is some 
evidence that hyperlipidemia promotes progression of kidney 
dysfunction, but there is no convincing evidence as yet that 
using statins to lower cholesterol reduces progression of 
kidney disease or reduces cardiovascular risk in patients with 
CKD. The ongoing SHARP study is examining cholesterol 
reduction with a combination of simvastatin and ezetimibe 
versus placebo and includes patients with CKD, so hopefully 
there will be a sound evidence base in the near future.
Given the high risk of vascular risk carried by patients 
with CKD, primary prevention with an anti platelet agent 
might seem to be a good additional measure. There are 
potential conflicts for physicians treating a patient after 
a coronary stent has been placed who may require clopidogrel 
and aspirin in which the risks of bleeding from Tenckhoff 
catheter insertion to allow peritoneal dialysis and kidney 
transplant surgery may be considered unacceptable for 
elective surgery.
Conclusion
Cardiovascular disease and kidney disease are linked 
by a common etiology and together result in a very 
poor prognosis. There are many incompletely understood 
pathological processes involved, especially in the early 
stages of CKD during which the scope for successful inter-
vention is huge and the benefits to the patient likely to be 
great. Physicians must be diligent to preview cardiovascular 
disease in patients with CKD and take appropriate measures 
to reduce patient risk, working with the patient to promote 
healthy living and compliance with prescribed medications. 
The place of specific prognostic investigations may also be 
considered. In one study, the presence and severity of renal 
dysfunction gave additional prognostic value over dobu-
tamine stress echocardiography findings for cardiac death 
and events.65 The presence and extent of ischemia on stress 
echocardiography is an independent predictor of death in 
patients with CKD, the effect of which remained even after 
patients had a renal transplant.66
This is an area demanding urgent and focused attention 
in an effort to break the deadly synergy between kidney and 
cardiovascular disease.
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